ASAlessandra Serra

Alessandra Serra

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Alessandra Serra has a total of 12 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    An evaluation of designs for Phase I/IIa dose-finding studies in Tuberculosis

    by Alessandra Serra, Pavel Mozgunov, Patrick Pj Phillips, Thomas Jaki

    Early development of tuberculosis (TB) treatments often separates dose-finding in healthy volunteers (Phase I) and safety and early activity in patients (Phase IIa). The BTZ-043 study (NCT04044001) is a recent study that combined these two objectives in patients in a single study. In this work, we describe and compare three different design options which consider safety and activity endpoints differently in the dose escalation process. In simulations we show that the design that incorporates information about activity together with safety in the dose escalation process allows more precise estimation of the optimal dose and leads to a higher power on average in selecting at least one suitable dose at the end of the study compared to the design that considers only the safety endpoint for dose escalation.

  • Open Access

    Adaptive Biomarker‐Based Design for Early Phase Clinical Trials

    by Alessandra Serra, Gaëlle Saint‐Hilary, Sandrine Guilleminot, Julia Geronimi, Pavel Mozgunov

    Identifying and quantifying predictive biomarkers is a critical issue of Precision Medicine approaches and patient‐centric clinical development strategies. Early phase adaptive designs can improve trial efficiency by allowing for adaptations during the course of the trial. In this work, we are interested in adaptations based on interim analysis permitting a refinement of the existing study population according to their predictive biomarkers. At an early stage, the goal is not to precisely define the target population, but to not miss an efficacy signal that might be limited to a biomarker subgroup. In this work, we propose a one‐arm two‐stage early phase biomarker‐guided design in the setting of an oncology trial where at the time of the interim analysis, several decisions can be made regarding stopping the entire trial early or continuing to recruit patients from the full or a selected patient population. Via simulations, we show that, although the sample size is limited, the proposed design leads to better decision‐making compared to a classical design that does not consider an enrichment expansion.


  • Open Access

    A Novel Approach to Assess the Predictiveness of a Continuous Biomarker in Early Phases of Drug Development

    by Alessandra Serra, Julia Geronimi, Sandrine Guilleminot, Hugo Hadjur, Marie‐Karelle Riviere, Gaëlle Saint‐Hilary, Pavel Mozgunov

    Identifying and quantifying predictive biomarkers is a critical issue of personalized medicine approaches and patient‐centric clinical development strategies. In early stages of the development process, significant challenges and numerous uncertainties arise. One of the challenges is the ability to assess the predictive value of a biomarker, i.e., the difference in primary outcomes between experimental and placebo arms above and below a certain threshold of the biomarker. Indeed, when the accumulated information is very limited and the sample size is small, preliminary conclusions about the predictive properties of the biomarker might be misleading. To date, the majority of investigations regarding the predictiveness of biomarkers were in the setting of moderate‐to‐large sample sizes. In this work, we propose a novel flexible approach inspired by the Kolmogorov‐Smirnov Distance in order to assess the predictiveness of a continuous biomarker in a clinical setting where the sample size is small. Via simulations we show that the proposed method allows to achieve a higher power to declare predictiveness compared to the existing methods under a range of scenarios, whilst still maintaining a control of the type I error at a pre‐specified level.


  • Open Access

    Determining the minimum duration of treatment in tuberculosis: An order restricted non‐inferiority trial design

    by Alessandra Serra, Pavel Mozgunov, Geraint Davies, Thomas Jaki

    Tuberculosis (TB) is one of the biggest killers among infectious diseases worldwide. Together with the identification of drugs that can provide benefits to patients, the challenge in TB is also the optimisation of the duration of these treatments. While conventional duration of treatment in TB is 6 months, there is evidence that shorter durations might be as effective but could be associated with fewer side effects and may be associated with better adherence. Based on a recent proposal of an adaptive order-restricted superiority design that employs the ordering assumptions within various duration of the same drug, we propose a non-inferiority (typically used in TB trials) adaptive design that effectively uses the order assumption. Together with the general construction of the hypothesis testing and expression for type I and type II errors, we focus on how the novel design was proposed for a TB trial concept. We consider a number of practical aspects such as choice of the design parameters, randomisation ratios, and timings of the interim analyses, and how these were discussed with the clinical team.


  • Open Access

    A Bayesian multi‐arm multi‐stage clinical trial design incorporating information about treatment ordering

    by Alessandra Serra, Pavel Mozgunov, Thomas Jaki

    Multi-Arm Multi-Stage (MAMS) designs can notably improve efficiency in later stages of drug development, but they can be suboptimal when an order in the effects of the arms can be assumed. In this work, we propose a Bayesian multi-arm multi-stage trial design that selects all promising treatments with high probability and can efficiently incorporate information about the order in the treatment effects as well as incorporate prior knowledge on the treatments. A distinguishing feature of the proposed design is that it allows taking into account the uncertainty of the treatment effect order assumption and does not assume any parametric arm-response model. The design can provide control of the family-wise error rate under specific values of the control mean and we illustrate its operating characteristics in a study of symptomatic asthma. Via simulations, we compare the novel Bayesian design with frequentist multi-arm multi-stage designs and a frequentist order restricted design that does not account for the order uncertainty and demonstrate the gains in the sample sizes the proposed design can provide. We also find that the proposed design is robust to violations of the assumptions on the order.


  • Open Access

    What is the expected benefit of patient-centric clinical development in oncology?

    by Alessandra Serra, Pavel Mozgunov, Thomas Jaki, Fabio Rigat

    The identification and quantification of predictive biomarkers characterize personalized medicine approaches and patient-centric clinical development. In practice, the sponsor needs evaluating whether biomarker-informed clinical development strategies are more likely to benefit current and future patients. To this end, a simple metric is proposed and assessed here quantifying the expected clinical benefit (ECB) of clinical development programmes. Using simulation scenarios and endpoints relevant to oncology, the ECB of a simple biomarker-informed strategy is shown to be specific and sensitive. Also, the ECB difference is shown to increase in the biomarker-driven incremental efficacy and with the population prevalence of biomarker-positive study participants.

  • Open Access

    An order restricted multi‐arm multi‐stage clinical trial design

    by Alessandra Serra, Pavel Mozgunov, Thomas Jaki

    One family of designs that can noticeably improve efficiency in later stages of drug development are multi-arm multi-stage (MAMS) designs. They allow several arms to be studied concurrently and gain efficiency by dropping poorly performing treatment arms during the trial as well as by allowing to stop early for benefit. Conventional MAMS designs were developed for the setting, in which treatment arms are independent and hence can be inefficient when an order in the effects of the arms can be assumed (eg, when considering different treatment durations or different doses). In this work, we extend the MAMS framework to incorporate the order of treatment effects when no parametric dose-response or duration-response model is assumed. The design can identify all promising treatments with high probability. We show that the design provides strong control of the family-wise error rate and illustrate the design in a study of symptomatic asthma. Via simulations we show that the inclusion of the ordering information leads to better decision-making compared to a fixed sample and a MAMS design. Specifically, in the considered settings, reductions in sample size of around 15% were achieved in comparison to a conventional MAMS design.